Gastroenterology
Volume 130, Issue 2 , Pages 548-565, February 2006

Differential and Epigenetic Gene Expression Profiling Identifies Frequent Disruption of the RELN Pathway in Pancreatic Cancers

  • Norihiro Sato

      Affiliations

    • Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
  • ,
  • Noriyoshi Fukushima

      Affiliations

    • Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
  • ,
  • Rubens Chang

      Affiliations

    • Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
  • ,
  • Hiroyuki Matsubayashi

      Affiliations

    • Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
  • ,
  • Michael Goggins

      Affiliations

    • Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    • Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    • Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland
    • Corresponding Author InformationAddress requests for reprints to: Michael Goggins, MD, Departments of Pathology, Medicine, and Oncology, The Sol Goldman Center for Pancreatic Cancer Research, The Johns Hopkins Medical Institutions, 632 Ross Building, 720 Rutland Avenue, Baltimore, Maryland 21205. fax: (410) 614-0671.

Received 2 September 2005; accepted 2 November 2005. published online 23 November 2005.

Background & Aims: Recently described genome-wide approaches robustly detect many candidate genes that are regulated by DNA methylation, but many of these genes do not represent important targets for functional inactivation. Here we used a microarray-based strategy to identify biologically relevant genes associated with epigenetic silencing in pancreatic cancer. Methods: We compared information from differential gene expression analysis with the transcriptional responses to epigenetic modifiers. Results: Using this approach, we identified 7 novel targets for aberrant methylation in pancreatic cancer. One of the genes identified, RELN (Reelin), a key regulator of neuronal migration, is frequently silenced in pancreatic cancers, as are several of its downstream mediators. Importantly, small interfering RNA–mediated knockdown of RELN in pancreatic cancer cells that retain RELN expression resulted in greatly enhanced cell motility, invasiveness, and colony-forming ability. Increased cell motility was also induced by knockdown of downstream components of the RELN pathway, including ApoER2, VLDLR, and DAB1. Treatment of pancreatic cancer cells with histone deacetylase inhibitors, valproic acid and suberoylanilide hydroxamic acid, restored the expression of RELN and DAB1 and markedly inhibited their migration. Conclusions: The high prevalence of the silencing of RELN pathway components and its reversal by histone deacetylase inhibitors suggest the importance of this pathway as a diagnostic and therapeutic target for pancreatic cancer.

Abbreviations used in this paper:  ApoER2, apolipoprotein E receptor 2 , COBRA, combined bisulfite restriction analysis , 5Aza-dC, 5-aza-2′-deoxycytidine , HDAC, histone deacetylase , IPMN, intraductal papillary mucinous neoplasm of the pancreas , MSP, methylation-specific polymerase chain reaction , PKB, protein kinase B , RT-PCR, reverse-transcription polymerase chain reaction , SAHA, suberoylanilide hydroxamic acid , siRNA, small interfering RNA , TSA, trichostatin A , VLDLR, very-low-density lipoprotein receptor , VPA, valproic acid

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by National Cancer Institute grants CA90709 and CA62924, the Michael Rolfe Foundation, and the National Pancreas Foundation.

PII: S0016-5085(05)02268-7

doi:10.1053/j.gastro.2005.11.008

Gastroenterology
Volume 130, Issue 2 , Pages 548-565, February 2006